CAS 284461-73-0
:Sorafenib
Description:
Sorafenib is a small-molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, including renal cell carcinoma and hepatocellular carcinoma. Its chemical formula is C21H16ClF2N3O3, and it features a complex structure that includes a pyridine ring, a phenyl group, and a urea moiety. Sorafenib functions by inhibiting multiple kinases involved in tumor cell proliferation and angiogenesis, specifically targeting the RAF kinase and various receptor tyrosine kinases. This multi-targeted approach helps to disrupt the signaling pathways that promote cancer growth and metastasis. Sorafenib is typically administered orally and has a moderate bioavailability, with its pharmacokinetics influenced by factors such as food intake. Common side effects include fatigue, diarrhea, and skin reactions. Due to its mechanism of action and therapeutic applications, Sorafenib represents a significant advancement in targeted cancer therapies, although its use may be limited by the development of resistance and the need for careful patient monitoring.
Formula:C28H24ClF3N4O6S
InChI:InChI=1/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
InChI key:InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2
Synonyms:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
- 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-Pyridinecarboxamide
- Bay 43-9006
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
- Nevaxar
- Sorafenib base
- Sorafenib
- SORAFENIB TOLSYLATE
- Sorafenib free base for research
- SORAFENIB-D3
- SORAFENIB MESYLATE
- BAY-43-900
- Sorafenib Tosylate(TINIBS)
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)-carboxamide
- RAF1 KINASE INHIBITOR II
- SORAFENIB(FORR&DONLY)
- Sorafenib Tosylate for research
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 14 products.
Sorafenib
CAS:Formula:C21H16ClF3N4O3Purity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:464.834-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
CAS:Formula:C21H16ClF3N4O3Purity:99%Color and Shape:SolidMolecular weight:464.8249Sorafenib
CAS:<p>Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57</p>Formula:C21H16ClF3N4O3Purity:98% - 99.89%Color and Shape:SolidMolecular weight:464.82Sorafenib
CAS:SorafenibFormula:C21H16ClF3N4O3Purity:98%Color and Shape: white solidMolecular weight:464.82g/molSorafenib
CAS:Formula:C21H16ClF3N4O3Purity:≥ 95.0%Color and Shape:White, off-white or light-yellow solidMolecular weight:464.83Sorafenib-d4
CAS:Controlled ProductFormula:C21H12D4ClF3N4O3Color and Shape:NeatMolecular weight:468.85Sorafenib - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Formula:C21H16ClF3N4O3Purity:Min. 98%Color and Shape:PowderMolecular weight:464.82 g/molSorafenib
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Formula:C21H16ClF3N4O3Purity:Min. 98.0 Area-%Color and Shape:White PowderMolecular weight:464.82 g/mol
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039KS.jpg&w=3840&q=75)
